The primary endpoint of the EPIC trial was death, MI, or urgent intervention at 30 days (placebo 12.8% [n=696], ReoPro 8.3% [n=708], P=0.008, relative reduction 35%).¹⁰
The primary endpoint of the EPILOG trial was death, MI, or urgent revascularization at 30 days (placebo + standard-dose heparin 11.7% [n=939], ReoPro + low-dose heparin 5.2% [n=935], P<0.001 vs placebo + standard-dose heparin, relative reduction 56%; ReoPro + standard-dose heparin 5.4% [n=918], P<0.001 vs placebo + standard-dose heparin, relative reduction 54%).¹¹
The primary endpoint of the CAPTURE trial was death, MI, or an urgent intervention within 30 days (placebo 15.9% [n=635] vs. ReoPro 11.3% [n=630], P=0.012). THe troponin data above are from patients without an MI within 14 days prior to randomization.¹²
The primary endpoint of the EPISTENT trial was death, MI or an urgent intervention within 30 days (placebo+stent 10.8% [n=809] vs. ReoPro+stent 5.3% [n=794], P<0.001). The troponin data above are from patients with an evaluable troponin T at baseline.¹³
The primary endpoint in TARGET was deathm MI, or an urgent intervention within 30 days (tirofiban 7.6% [n=2398] vs. ReoPro+stent 6.0% [n=2411], P=0.038). The troponin data above are from patients with a recent MI.¹⁴